Chronic Refractory Cough (CRC) - Epidemiology Forecast to 2028

Description Table of
Contents

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

‘Chronic Refractory Cough (CRC)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Chronic Refractory Cough (CRC) - Epidemiology
Chronic refractory cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialties: Pulmonology, Allergy, and Immunology, Digestive Health and Otorhinolaryngology. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough which may be localized to the laryngeal region. Chronic cough lasts more than 8 weeks and can be caused by gastroesophageal reflux disease (GERD), postnasal drip from sinus infections or allergies, or chronic lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and interstitial lung diseases.

The Chronic Refractory Cough Epidemiology report gives the thorough understanding of the Chronic Refractory Cough by including details such as disease introduction, signs and symptoms, causes, risk factors, mechanism of Chronic cough, pathophysiology, the similarity between Chronic Refractory Cough and other neuropathic disorder diagnoses, pathogenesis, clinical features of CRC and diagnosis provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Chronic Refractory Cough are studied through all possible division to give a better understanding of the disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, research papers, and views of key opinion leaders.

Chronic Refractory Cough (CRC) Epidemiology
In the United States, cough is the most common complaint for which patients seek medical attention and is the second most common reason for a general medical examination, accounting for more than 26 million office visits annually. Cough often results from an acute, self-limited, viral upper respiratory tract infection; however, there are multiple causes of cough beyond this, including both respiratory tract and nonrespiratory tract-related etiologies. Cough that lasts more than 8 weeks is considered to be chronic as per defined by the American College of Chest Physicians (ACCP). The cough becomes chronic if it persists, often due to an underlying etiology that is difficult to diagnose or treat.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Chronic Refractory Cough in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2028 for the following aspects:

Prevalent Population of Chronic Cough
Gender-wise Prevalent Population of Chronic Cough
Prevalent Population of Chronic Refractory Cough
Diagnosed Prevalent Population of Chronic Refractory Cough
Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients

According to a study conducted by Jun et al. titled “Effect of pregabalin for the treatment of chronic refractory cough,” which stated that nearly 11–16% of patients suffer from chronic refractory cough during their life. Although many patients had received satisfactory treatment, there were still 20–40% of patients who suffered long-term cough symptoms even after standardized treatment. The study was concluded stating that an innovative treatment with fewer adverse effects and long-term relief was necessary for CRC patients.

According to a study conducted by Weinberger et al. titled “Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens” researchers assessed the burden of suffering related to prolonged coughing and tried to identify further causative agents. It was found that incidence of pertussis in adults have shown that it accounted for only approximately 5–15% cases of prolonged coughing in which, symptoms were not indicative of a specific agent and a total of 64% of patients received antibiotics. The study was concluded by stating that prolonged adult coughing required medical attention, which prompted substantial healthcare use.

Report Scope

The report covers a detailed overview of Chronic Refractory Cough explaining its causes, symptoms, and classification, pathophysiology, and diagnosis and treatment patterns.
The report provides the insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Chronic Refractory Cough
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Key Strengths

10 Year Forecast of Chronic Refractory Cough epidemiology
7MM Coverage
Total Prevalent Cases of Chronic Refractory Cough
Prevalent Cases according to the segmentation

Key Assessments

Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Note: Product cover images may vary from those shown

LOGIN TO ACCESS EXECUTIVE SUMMARY
PRINTER FRIENDLY

1. Key Insights

2. Disease Background and Overview: Chronic Refractory Cough (CRC)
2.1. Introduction
2.2. Signs and symptoms
2.3. Causes
2.4. Risk factors
2.5. Mechanism of Chronic cough
2.6. Pathophysiology of chronic cough
2.7. Similarity between Chronic Refractory Cough and other neuropathic disorder
2.7.1. Cough hypersensitivity syndrome and Chronic Refractory Cough
2.7.2. Laryngeal hypersensitivity
2.8. Pathogenesis of Chronic Refractory Cough
2.9. Clinical features of CRC
2.10. Diagnosis

3. Epidemiology and Patient Population: Key Findings
3.1. 7MM Total Patient Population of Chronic Refractory Cough
3.2. 7MM Total Diagnosed Patient Population of Chronic Refractory Cough

4. Country Wise-Epidemiology of Chronic Refractory Cough
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Chronic Cough Prevalent Population in the United States
4.1.3. Chronic Cough Gender-wise Prevalent Population in the United States
4.1.4. Chronic Refractory Cough Prevalent Population in the United States
4.1.5. Chronic Refractory Cough Diagnosed Prevalent Population in the United States
4.1.6. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Chronic Cough Prevalent Population in Germany
4.3.2. Chronic Cough Gender-wise Prevalent Population in Germany
4.3.3. Chronic Refractory Cough Prevalent Population in Germany
4.3.4. Chronic Refractory Cough Diagnosed Prevalent Population in Germany
4.3.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Germany
4.4. France
4.4.1. Chronic Cough Prevalent Population in France
4.4.2. Chronic Cough Gender-wise Prevalent Population in France
4.4.3. Chronic Refractory Cough Prevalent Population in France
4.4.4. Chronic Refractory Cough Diagnosed Prevalent Population in France
4.4.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in France
4.5. Italy
4.5.1. Chronic Cough Prevalent Population in Italy
4.5.2. Chronic Cough Gender-wise Prevalent Population in Italy
4.5.3. Chronic Refractory Cough Prevalent Population in Italy
4.5.4. Chronic Refractory Cough Diagnosed Prevalent Population in Italy
4.5.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Italy
4.6. Spain
4.6.1. Chronic Cough Prevalent Population in Spain
4.6.2. Chronic Cough Gender-wise Prevalent Population in Spain
4.6.3. Chronic Refractory Cough Prevalent Population in Spain
4.6.4. Chronic Refractory Cough Diagnosed Prevalent Population in Spain
4.6.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Spain
4.7. United Kingdom
4.7.1. Chronic Cough Prevalent Population in the United Kingdom
4.7.2. Chronic Cough Gender-wise Prevalent Population in the United Kingdom
4.7.3. Chronic Refractory Cough Prevalent Population in the United Kingdom
4.7.4. Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom
4.7.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Chronic Cough Prevalent Population in Japan
4.8.3. Chronic Cough Gender-wise Prevalent Population in Japan
4.8.4. Chronic Refractory Cough Prevalent Population in Japan
4.8.5. Chronic Refractory Cough Diagnosed Prevalent Population in Japan
4.8.6. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Japan

5. Appendix
5.1. Report Methodology

6. Capabilities

7. Disclaimer

8. About the Author

List of Tables
Table 1 Total Population of Chronic Refractory Cough in the 7MM (2017–2028)
Table 2 Total Diagnosed Population of Chronic Refractory Cough in the 7MM (2017–2028)
Table 3 Chronic Cough Prevalent Population in the United States (2017–2028)
Table 4 Chronic Cough Gender-wise Prevalent Population in the United States (2017–2028)
Table 5 Chronic Refractory Cough Prevalent Population in the United States (2017–2028)
Table 6 Chronic Refractory Cough Diagnosed Prevalent Population in the United States (2017–2028)
Table 7 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United States (2017–2028)
Table 8: Chronic Cough Prevalent Population in Germany (2017–2028)
Table 9 Chronic Cough Gender-wise Prevalent Population in Germany (2017–2028)
Table 10 Chronic Refractory Cough Prevalent Population in Germany (2017–2028)
Table 11 Chronic Refractory Cough Diagnosed Prevalent Population in Germany (2017–2028)
Table 12 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Germany (2017–2028)
Table 13 Chronic Cough Prevalent Population in France (2017–2028)
Table 14 Chronic Cough Gender-wise Prevalent Population in France (2017–2028)
Table 15 Chronic Refractory Cough Prevalent Population in France (2017–2028)
Table 16 Chronic Refractory Cough Diagnosed Prevalent Population in France (2017–2028)
Table 17 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in France (2017–2028)
Table 18 Chronic Cough Prevalent Population in Italy (2017–2028)
Table 19 Chronic Cough Gender-wise Prevalent Population in Italy (2017–2028)
Table 20 Chronic Refractory Cough Prevalent Population in Italy (2017–2028)
Table 21 Chronic Refractory Cough Diagnosed Prevalent Population in Italy (2017–2028)
Table 22 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Italy (2017–2028)
Table 23 Chronic Cough Prevalent Population in Spain (2017–2028)
Table 24 Chronic Cough Gender-wise Prevalent Population in Spain (2017–2028)
Table 25 Chronic Refractory Cough Prevalent Population in Spain (2017–2028)
Table 26 Chronic Refractory Cough Diagnosed Prevalent Population in Spain (2017–2028)
Table 27 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Spain (2017–2028)
Table 28 Chronic Cough Prevalent Population in the United Kingdom (2017–2028)
Table 29 Chronic Cough Gender-wise Prevalent Population in the United Kingdom (2017–2028)
Table 30 Chronic Refractory Cough Prevalent Population in the United Kingdom(2017–2028)
Table 31 Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 32 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United Kingdom (2017–2028)
Table 33 Prevalent Population of Chronic Cough in Japan (2017–2028)
Table 34 Gender-wise Prevalent Population of Chronic Cough in Japan (2017–2028)
Table 35 Prevalent Population of Chronic Refractory Cough in Japan(2017–2028)
Table 36 Diagnosed Prevalent Population of Chronic Refractory Cough in Japan (2017–2028)
Table 37 Diagnosed Prevalent Population of Chronic Refractory Cough in IPF patients in Japan (2017–2028)
Table 38 Comparison of cough guidelines in relation to chronic refractory cough (CRC)

List of Figures
Figure 1 Symptoms of Chronic Refractory Cough
Figure 2 Origins and neurological pathways of the cough reflex.
Figure 3 Total Patient Population of Chronic Refractory Cough in the 7MM (2017–2028)
Figure 4 Total Diagnosed Patient Population of Chronic Refractory Cough in the 7MM (2017–2028)
Figure 5 Chronic Cough Prevalent Population in the United States (2017–2028)
Figure 6 Chronic Cough Gender-wise Prevalent Population in the United States (2017–2028)
Figure 7 Chronic Refractory Cough Prevalent Population in the United States (2017–2028)
Figure 8 Chronic Refractory Cough Diagnosed Prevalent Population in the United States (2017–2028)
Figure 9 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United States (2017–2028)
Figure 10 Chronic Cough Prevalent Population in Germany (2017–2028)
Figure 11 Chronic Cough Gender-wise Prevalent Population in Germany (2017–2028)
Figure 12 Chronic Refractory Cough Prevalent Population in Germany (2017–2028)
Figure 13 Chronic Refractory Cough Diagnosed Prevalent Population in Germany (2017–2028)
Figure 14 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Germany (2017–2028)
Figure 15 Chronic Cough Prevalent Population in France (2017–2028)
Figure 16 Chronic Cough Gender-wise Prevalent Population in France (2017–2028)
Figure 17 Chronic Refractory Cough Prevalent Population in France (2017–2028)
Figure 18 Chronic Refractory Cough Diagnosed Prevalent Population in France (2017–2028)
Figure 19 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in France (2017–2028)
Figure 20 Chronic Cough Prevalent Population in Italy (2017–2028)
Figure 21 Chronic Cough Gender-wise Prevalent Population in Italy (2017–2028)
Figure 22 Chronic Refractory Cough Prevalent Population in Italy (2017–2028)
Figure 23 Chronic Refractory Cough Diagnosed Prevalent Population in Italy (2017–2028)
Figure 24 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Italy (2017–2028)
Figure 25 Chronic Cough Prevalent Population in Spain (2017–2028)
Figure 26 Chronic Cough Gender-wise Prevalent Population in Spain (2017–2028)
Figure 27 Chronic Refractory Cough Prevalent Population in Spain (2017–2028)
Figure 28 Chronic Refractory Cough Diagnosed Prevalent Population in Spain (2017–2028)
Figure 29 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Spain (2017–2028)
Figure 30 Chronic Cough Prevalent Population in the United Kingdom (2017–2028)
Figure 31 Chronic Cough Gender-wise Prevalent Population in the United Kingdom (2017–2028)
Figure 32 Chronic Refractory Cough Prevalent Population in the United Kingdom(2017–2028)
Figure 33 Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 34 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United Kingdom (2017–2028)
Figure 35 Prevalent Population of Chronic Cough in Japan (2017–2028)
Figure 36 Gender-wise Prevalent Population of Chronic Cough in Japan (2017–2028)
Figure 37 Prevalent Population of Chronic Refractory Cough in Japan(2017–2028)
Figure 38 Diagnosed Prevalent Population of Chronic Refractory Cough in Japan (2017–2028)
Figure 39 Diagnosed Prevalent Population of Chronic Refractory Cough in IPF patients in Japan (2017–2028)

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

Chronic Refractory Cough (CRC) - Epidemiology Forecast to 2030

Chronic Refractory Cough - Market Insight, Epidemiology and Market Forecast - 2030

Cough Hypersensitivity Syndrome Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029

Chronic Cough (Respiratory) - Drugs in Development, 2021